Filing Details
- Accession Number:
- 0000899243-21-009370
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-03-03 16:05:17
- Reporting Period:
- 2021-03-01
- Accepted Time:
- 2021-03-03 16:05:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1661998 | Homology Medicines Inc. | FIXX | Pharmaceutical Preparations (2834) | 473468154 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1754067 | P Timothy Kelly | C/O Homology Medicines, Inc. One Patriots Park Bedford MA 01730 | See Remarks. | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-03-01 | 2,000 | $6.63 | 4,232 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-03-01 | 2,000 | $2.89 | 6,232 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2021-03-01 | 6,232 | $11.16 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Options | Disposition | 2021-03-01 | 2,000 | $0.00 | 2,000 | $6.63 |
Common Stock | Employee Stock Options | Disposition | 2021-03-01 | 2,000 | $0.00 | 2,000 | $2.89 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
41,500 | 2027-12-06 | No | 4 | M | Direct | |
32,001 | 2027-09-06 | No | 4 | M | Direct |
Footnotes
- Includes 2,232 shares acquired under Issuer's Employee Stock Purchase Plan on February 26, 2021.
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2020.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $10.9600 to $11.3100. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018, so that such option will become fully vested on January 1, 2022.
- The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was May 30, 2017.